A Study to Evaluate ALN-4915 in Adult Healthy Volunteers
ConditionHealthy Volunteers
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-65
SponsorAlnylam Pharmaceuticals
About this trial
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of ALN-4915.
Eligibility criteria
Qualifiers
Is willing and able to complete all study assessments
Disqualifiers
Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >upper limit of normal (ULN)
Has total bilirubin >ULN
Has no history of invasive infection by an encapsulated organism
Has no known complement or immunologic deficiency
Trial design
Treatments tested in this trial
- ALN-4915
- Placebo
Treatment groups
44 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov